Limoclav

Short-term treatment of bacterial infections in adults at following sites when caused by susceptible organisms: URTI (including ENT) eg, recurrent tonsillitis, sinusitis, otitis media, typically caused by Strep pneumoniae, H. influenzae, Moraxella catarrhalis, & Strep pyogenes; lower resp tract eg, acute exacerbations of chronic bronchitis, lobar, & bronchopneumonia, typically caused by Strep pneumoniae, H. influenzae, & Moraxella catarrhalis; GUT eg, cystitis, urethritis, pyelonephritis, & female genital infections typically caused by Enterobacteriaceae (mainly E. coli), Staph saprophyticus & Enterococcus sp & gonorrhea caused by Neisseria gonorrhoeae; skin & soft tissue typically caused by Staph aureus, Strep pyogenes, & Bacteroides sp; bone & joint eg, osteomyelitis typically caused by Staph aureus, where more prolonged therapy may be appropriate; other infections eg, septic abortion, puerperal & intraabdominal sepsis.

Adult 1 tab tid.

May be taken with or without food: Best taken at the start of a meal for optimized absorption & reduced GI reactions.

Hypersensitivity to β-lactams eg, penicillins & cephalosporins. History of amoxicillin-clavulanate associated jaundice/hepatic dysfunction.

Perform careful inquiry concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens before initiating therapy. Discontinue therapy & institute appropriate alternative therapy if allergic reaction occurs. Avoid if infectious mononucleosis is suspected. Prolonged use may result in overgrowth of non-susceptible organisms. Consider pseudomembranous colitis diagnosis in patients who develop diarrhea during or after antibiotic use. Discontinue treatment immediately & further investigate if prolonged or significant diarrhea occurs or patient experiences abdominal cramps. Periodic assessment of organ system functions, including renal, hepatic, & hematopoietic function during prolonged therapy is advisable. Perform appropriate monitoring of prothrombin time when anticoagulants are prescribed concurrently. Risk of crystalluria in patients w/ reduced urine output. Maintain adequate fluid intake & urinary output. Changes in LFTs in some patients receiving therapy. Use w/ caution in patients w/ evidence of hepatic dysfunction. Rare reports of cholestatic jaundice. Avoid use during pregnancy, unless considered essential. May be administered during period of lactation.

Diarrhea, pseudo membrane colitis, emesis, indigestion, nausea, & stomatitis; moderate rise in AST (SGOT) &/or ALT (SGPT); skin rashes (urticarial & erythematous rashes); reversible leucopenia (including hypersensitivity & granulocytopenia), reversible thrombocytopenia & hemolytic anemia, thrombocytopenic purpura, eosinophilia, leucosis, agranulocytosis; convulsions in patients w/ impaired renal functions or receiving high dose.

May affect gut flora, leading to lower oestrogen reabsorption & reduced efficacy of combined OCs. Reduction in pre-dose conc of active metabolite mycophenolic acid in patients receiving mycophenolate mofetil. Amoxicillin: Decreased renal tubular secretion that may result in increased & prolonged blood levels w/ probenecid. Increased likelihood of allergic skin reactions w/ allopurinol. Rare cases of increased INR in patients maintained on acenocoumarol or warfarin.

Penicillins

J01CR02 - amoxicillin and beta-lactamase inhibitor ; Belongs to the class of penicillin combinations, including beta-lactamase inhibitors. Used in the systemic treatment of infections.

Rx